Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
The November 2000 NIH report of the Brain Tumor Progress Review Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.
Doolittle
Nancy D
ND
Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road-L603, Portland, OR 97201-3098, USA.
Abrey
Lauren E
LE
Ferrari
Nicolay
N
Hall
Walter A
WA
Laws
Edward R
ER
McLendon
Roger E
RE
Muldoon
Leslie L
LL
Peereboom
David
D
Peterson
Darryl R
DR
Reynolds
C Patrick
CP
Senter
Peter
P
Neuwelt
Edward A
EA
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D004343:Drug Implants; D006801:Humans
D000970:Antineoplastic Agents; D004343:Drug Implants